Lasofoxifene
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Lasofoxifene?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy,[1][2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Fablyn |
Routes of administration | By mouth |
Drug class | Selective estrogen receptor modulator |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H31NO2 |
Molar mass | 413.55 g/mol 563.64 g/mol (tartrate) g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close